EGUALEN SODIUM

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H17O3S.Na
Molecular Weight	300.348
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

[Na+].CCC1=CC(=C2C=C(C=CC=C12)C(C)C)S([O-])(=O)=O

InChI

InChIKey=KXGWXVVNYQOMQZ-UHFFFAOYSA-M

InChI=1S/C15H18O3S.Na/c1-4-11-9-15(19(16,17)18)14-8-12(10(2)3)6-5-7-13(11)14;/h5-10H,4H2,1-3H3,(H,16,17,18);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	C15H17O3S
Molecular Weight	277.359
Charge	-1
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Egualen is an azulene derivative developed for the treatment of peptic ulcer and marketed in Japan under the tradename Azuloxa. The drug exerts its antiulcer activity by antagonizing TXA2 production.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
thromboxane A2 signaling pathway 5	Antagonist 2,849
gastric mucosal blood circulation 6	Activator 1,447
mucus secretion 8	Activator 1,447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastric ulcer 74	Primary		Approved 8,583	AZULOXA

C_max

Value	Dose	Analyte	Population
1272 ng/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
1417.7 ng/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
0.6 μg/mL	10 mg single, oral	EGUALEN plasma	Homo sapiens
0.58 μg/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
1.84 μg/mL	30 mg single, oral	EGUALEN plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
10744.1 ng × h/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
11710.9 ng × h/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
6 μg × h/mL	10 mg single, oral	EGUALEN plasma	Homo sapiens
7.2 μg × h/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
18.2 μg × h/mL	30 mg single, oral	EGUALEN plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
7.8 h	15 mg single, oral	EGUALEN plasma	Homo sapiens
7.9 h	15 mg single, oral	EGUALEN plasma	Homo sapiens
4.6 h	10 mg single, oral	EGUALEN plasma	Homo sapiens
5.9 h	15 mg single, oral	EGUALEN plasma	Homo sapiens
4.4 h	30 mg single, oral	EGUALEN plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
1.7%			EGUALEN plasma	Homo sapiens
0.2%	15 mg single, oral		EGUALEN plasma	Homo sapiens

Doses

Doses

Show entries

Dose	Population	Adverse events
1.2 g 1 times / day multiple, oral Highest studied dose	healthy, ADULT

Showing 1 to 1 of 1 entries

Previous1Next

PubMed

PubMed

Show entries

Title	Date	PubMed
Inhibitory effect of egualen sodium: a new stable derivative of azulene on histamine release from mast cell-like cells in the stomach.	2001	11729358
A ring expansion-annulation strategy for the synthesis of substituted azulenes. Preparation and Suzuki coupling reactions of 1-azulenyl triflates.	2001 Apr 5	11277800

Showing 1 to 2 of 2 entries

Previous1Next

Sample Use Guides

In Vivo Use Guide

1 tablet (15 mg) or 0.6 g of 2.5% granules twice a day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical
Record UNII	3368L0W034
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

KT 1-32

Preferred Name

English

EGUALEN SODIUM

Common Name

English

1-AZULENESULFONIC ACID, 3-ETHYL-7-(1-METHYLETHYL)-, SODIUM SALT (1:1)

Common Name

English

3-ETHYL-7-ISOPROPYL-1-AZULENESULFONIC ACID SODIUM SALT

Common Name

English

Egualen sodium [WHO-DD]

Common Name

English

Showing 1 to 5 of 8 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

EPA CompTox

DTXSID8048787

PRIMARY

FDA UNII

3368L0W034

PRIMARY

EVMPD

SUB32240

PRIMARY

CAS

97683-31-3

PRIMARY

SMS_ID

100000124417

PRIMARY

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					17VM9WN49U

EGUALEN

PARENT -> SALT/SOLVATE

249501B040

EGUALEN SODIUM HYDRATE

SOLVATE->ANHYDROUS

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Related Record

Type

Details


					17VM9WN49U

EGUALEN

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Description<div class="info-popup-container"><div><span class="pop-sub-key ">Sources:&nbsp;</span><span class="pop-sub-val"><span class="ext-link"><a target="_self" href="http://www.ncbi.nlm.nih.gov/pubmed/23568973">http://www.ncbi.nlm.nih.gov/pubmed/23568973</a></span></span></div></div>

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

PubMed

Sample Use Guides

Description

C_max

T_1/2

F_unbound